Covid 19 Research using Clinical Trials (Home Page)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
|
Name (Synonyms) |
Correlation |
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D018450 | Disease Progression NIH | 0.24 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
This is a phase II/III randomised, multi-centre, prospective, open label, community-based
clinical trial. The trial aims to recruit patients who test positive for COVID-19 but who
have mild disease and therefore can treat their symptoms in the community. Patients who seek
testing and have a confirmed positive test result will be invited to enrol in the trial.
NCT04455815 COVID-19 Infection Drug: Camostat
Primary Outcomes
Measure: Number of participants who require hospital admission and require supplemental oxygen. Time: Days 1-28
Secondary Outcomes
Measure: Rate of COVID-19 related hospital admission in patients with SARS-CoV-2 infection. Time: Days 1-28 from randomisation.
Measure: Number of supplementary oxygen-free days at 28 days (from randomisation). Time: Days 1-28 from randomisation.
Measure: Number of ventilator-free days at 28 days (from randomisation). Time: Days 1-28 from randomisation.
Measure: To evaluate overall mortality. Time: one year from randomisation.
Measure: Time to worst point on the scale or deterioration of two points or more (from randomisation) on a 9-point category ordinal scale. Time: Days 1-28.
No related HPO nodes (Using clinical trials)